{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Neoplasia&page=10",
    "query": {
      "condition": "Gastrointestinal Neoplasia",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 7416,
    "total_pages": 742,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Neoplasia&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Neoplasia&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T00:16:19.061Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00515411",
      "title": "Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastroesophageal Junction Adenocarcinoma",
        "Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "Docetaxel, Leucovorin, Fluorouracil, Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2006-10-23",
      "completion_date": "2018-10-26",
      "has_results": true,
      "last_update_posted_date": "2019-12-10",
      "last_synced_at": "2026-10-15T00:16:19.061Z",
      "location_count": 15,
      "location_summary": "Duarte, California • Pembroke Pines, Florida • Atlanta, Georgia + 11 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00515411"
    },
    {
      "nct_id": "NCT01829971",
      "title": "A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Primary Liver Cancer",
        "SCLC",
        "Lymphoma",
        "Melanoma",
        "Multiple Myeloma",
        "Renal Cell Carcinoma",
        "NSCLC"
      ],
      "interventions": [
        {
          "name": "MRX34",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mirna Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 155,
      "start_date": "2013-04",
      "completion_date": "2017-05",
      "has_results": false,
      "last_update_posted_date": "2016-09-27",
      "last_synced_at": "2026-10-15T00:16:19.061Z",
      "location_count": 6,
      "location_summary": "Scottsdale, Arizona • Dallas, Texas • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01829971"
    },
    {
      "nct_id": "NCT02807844",
      "title": "Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Triple Negative Breast Cancer",
        "Pancreatic Carcinoma",
        "Melanoma",
        "Endometrial Carcinoma"
      ],
      "interventions": [
        {
          "name": "MCS110",
          "type": "DRUG"
        },
        {
          "name": "PDR001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 141,
      "start_date": "2016-06-29",
      "completion_date": "2020-06-04",
      "has_results": true,
      "last_update_posted_date": "2021-08-11",
      "last_synced_at": "2026-10-15T00:16:19.061Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • St Louis, Missouri • Germantown, Tennessee + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Germantown",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02807844"
    },
    {
      "nct_id": "NCT01896531",
      "title": "A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "5-Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Ipatasertib",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 153,
      "start_date": "2013-08-14",
      "completion_date": "2021-01-26",
      "has_results": true,
      "last_update_posted_date": "2022-03-02",
      "last_synced_at": "2026-10-15T00:16:19.061Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • Houston, Texas",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01896531"
    },
    {
      "nct_id": "NCT01682031",
      "title": "Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chemotherapeutic Agent Toxicity",
        "Mucositis",
        "Radiation Toxicity",
        "Stage III Squamous Cell Carcinoma of the Hypopharynx",
        "Stage III Squamous Cell Carcinoma of the Larynx",
        "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage III Squamous Cell Carcinoma of the Nasopharynx",
        "Stage III Squamous Cell Carcinoma of the Oropharynx",
        "Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Squamous Cell Carcinoma of the Hypopharynx",
        "Stage IV Squamous Cell Carcinoma of the Larynx",
        "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IV Squamous Cell Carcinoma of the Nasopharynx",
        "Stage IV Squamous Cell Carcinoma of the Oropharynx",
        "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Xerostomia"
      ],
      "interventions": [
        {
          "name": "selenomethionine",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER",
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2009-06",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2014-08-22",
      "last_synced_at": "2026-10-15T00:16:19.061Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01682031"
    },
    {
      "nct_id": "NCT02389751",
      "title": "Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastroesophageal Junction Adenocarcinoma",
        "Malignant Neoplasm of the Cervical Esophagus",
        "Malignant Neoplasm of the Thoracic Esophagus",
        "Stage IIA Esophageal Cancer AJCC v7",
        "Stage IIB Esophageal Cancer AJCC v7",
        "Stage IIIA Esophageal Cancer AJCC v7",
        "Stage IIIB Esophageal Cancer AJCC v7",
        "Stage IIIC Esophageal Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Ganetespib",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2015-04-10",
      "completion_date": "2019-07-16",
      "has_results": false,
      "last_update_posted_date": "2019-07-24",
      "last_synced_at": "2026-10-15T00:16:19.061Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02389751"
    },
    {
      "nct_id": "NCT00867477",
      "title": "PMRR-NO: Pulmonary Metabolic Radiation Response Versus Exhaled Nitric Oxide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastrointestinal Disease",
        "Esophageal Cancer",
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Breathing Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Respiratory Symptoms Questionnaire",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Pet Scan",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BEHAVIORAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 163,
      "start_date": "2009-03",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2014-08-28",
      "last_synced_at": "2026-10-15T00:16:19.061Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00867477"
    },
    {
      "nct_id": "NCT07001592",
      "title": "Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastric Neoplasms",
        "Esophageal Cancer",
        "Liver Cancer",
        "Liver Metastasis",
        "MSS-CRC",
        "MSS",
        "Gastric Adenocarcinoma",
        "Peritoneal Cancer",
        "Peritoneal Carcinoma",
        "Peritoneal Metastases",
        "MSI-H",
        "Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "vvDD-hIL-2-RG-1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 18,
      "start_date": "2025-05-06",
      "completion_date": "2028-05",
      "has_results": false,
      "last_update_posted_date": "2025-06-03",
      "last_synced_at": "2026-10-15T00:16:19.061Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07001592"
    },
    {
      "nct_id": "NCT03919292",
      "title": "Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "Neratinib",
          "type": "DRUG"
        },
        {
          "name": "Divalproex Sodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 83,
      "start_date": "2019-05-01",
      "completion_date": "2031-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-29",
      "last_synced_at": "2026-10-15T00:16:19.061Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03919292"
    },
    {
      "nct_id": "NCT06545331",
      "title": "Study of XB010 in Subjects With Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced or Metastatic Solid Tumors",
        "Esophageal Squamous Cell Cancer",
        "Head and Neck Squamous Cell Cancer",
        "NSCLC (Non-small Cell Lung Cancer)",
        "Hormone-receptor-positive Breast Cancer",
        "Triple Negative Breast Cancer (TNBC)"
      ],
      "interventions": [
        {
          "name": "XB010",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Exelixis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 396,
      "start_date": "2024-08-06",
      "completion_date": "2027-10-20",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-10-15T00:16:19.061Z",
      "location_count": 16,
      "location_summary": "Irvine, California • Los Angeles, California • Washington D.C., District of Columbia + 12 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06545331"
    }
  ]
}